Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer.
Expression of LRIG1 is Associated With Good Prognosis for Human Non-small Cell Lung Cancer.
复制标题
DOI：
10.1097/md.0000000000002081
复制
发表时间：
2015-11
期刊：
影响因子：
1.6
通讯作者：
Wang G
中科院分区：
文献类型：
--
作者：
An Y;Zhao Z;Ou P;Wang G
与靶向治疗的一定应答率相关的体细胞突变普遍存在于人类非小细胞肺癌（NSCLC）中。然而，在很大程度上尚不清楚哪组患者可能受益于针对不同体细胞突变的相应治疗。因此，迫切需要更有效的预后和预测标志物来治疗携带不同体细胞突变的NSCLC。富含亮氨酸重复序列和免疫球蛋白样结构域（LRIG）-1是属于LRIG家族的肿瘤抑制基因。LRIG 1表达在多种人类癌症中具有预后意义。在本研究中，我们首先使用定量聚合酶链反应（qPCR）和免疫组化分析分别对36例和182例NSCLC组织中LRIG 1的表达进行了分析。为了研究LRIG 1在非小细胞肺癌中的预后价值，我们采用考克斯比例风险回归分析了临床特征与总生存期（OS）之间的相关性。我们还通过Logistic回归分析比较LRIG 1在NSCLC预后中的敏感性和特异性，以进一步评估LRIG 1在NSCLC预后中的有效性。我们发现LRIG 1的表达与NSCLC的病理类型、分化程度和分期有关。结果表明LRIG 1是影响NSCLC患者OS的独立预后因素。LRIG 1与其他临床病理风险因素的组合是一个更强的预后模型比单独的临床病理风险因素。因此，LRIG 1表达可能在指导NSCLC患者的个人治疗方面提供了重要的临床价值。
Somatic mutations, which are associated with a certain rate of response to targeted therapies, are ubiquitously found in human non-small cell lung cancer (NSCLC). However, it is largely unknown which group of patients may benefit from the respective treatments targeting different somatic mutations. Therefore, more effective prognostic and predictive markers are desperately needed for the treatment of NSCLC harboring different somatic mutations. The leucine-rich repeats and immunoglobulin-like domains (LRIG)-1 is a tumor suppressor gene that belongs to the LRIG family. LRIG1 expression has prognostic significance in various human cancers. In this study, we first used the quantitative polymerase chain reaction (qPCR) and immunohistochemical analysis of 36 and 182 NSCLC patient tissues to analyze the LRIG1 expression respectively. To investigate the prognostic value of LRIG1 in NSCLC, we examined the correlation between clinical features and overall survival (OS) with Cox proportional hazard regression. We also compared the sensitivity and specificity of LRIG1 in NSCLC prognosis by logistic regression to further evaluate the prognostic efficiency of LRIG1 in NSCLC. We found that the LRIG1 expression was associated with pathological type, differentiation status, and stage of NSCLC. The result showed that LRIG1 was an independent prognostic factor for OS of NSCLC patients. LRIG1 in combination with other clinicopathological risk factors was a stronger prognostic model than clinicopathological risk factors alone. Thus, the LRIG1 expression potentially offered a significant clinical value in directing personal treatment for NSCLC patients.